Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan for Patients With Relapsed or Refractory Neuroblastoma

NCT02030964 is registered in ClinicalTrials.gov with New Approaches to Neuroblastoma Therapy Consortium as lead sponsor.

NCT NCT02030964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02030964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan for Patients With Relapsed or Refractory Neuroblastoma
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Phase
Phase 1
Overall status
Completed
Start date
January 16, 2014
Completion date
December 30, 2023
Enrollment
30 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma